Annals of Hematology

, Volume 89, Issue 6, pp 563–568 | Cite as

Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study

  • Sung Yong Oh
  • Won Seog Kim
  • Jin Seok Kim
  • Seok Jin Kim
  • Hyuk-Chan Kwon
  • Dae Ho Lee
  • Jong Ho Won
  • In Gyu Hwang
  • Min Kyoung Kim
  • Soon Il Lee
  • Yee Soo Chae
  • Deok-Hwan Yang
  • Gyeong-Won Lee
  • Chul Won Choi
  • Jinny Park
  • Cheolwon Suh
  • Hyo-Jin Kim
Original Article

Abstracts

Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34–79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n = 22), chemotherapy (n = 28), or radiotherapy (n = 6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6–8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease—characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.

Keywords

Pulmonary Marginal zone B-cell lymphoma Chemotherapy 

References

  1. 1.
    Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC (2000) Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg 69:993–997CrossRefPubMedGoogle Scholar
  2. 2.
    Ahmed S, Siddiqui AK, Rai KR (2002) Low-grade B-cell bronchial associated lymphoid tissue (BALT) lymphoma. Cancer Investig 20:1059–1068CrossRefGoogle Scholar
  3. 3.
    Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, Lopez-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489–2495CrossRefPubMedGoogle Scholar
  4. 4.
    Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K (2007) Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82:446–452CrossRefPubMedGoogle Scholar
  5. 5.
    Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH (1989) Structure and function of bronchus-associated lymphoid tissue (BALT). Crit Rev Immunol 9:119–150PubMedGoogle Scholar
  6. 6.
    Pabst R, Gehrke I (1990) Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am J Respir Cell Mol Biol 3:131–135PubMedGoogle Scholar
  7. 7.
    Richmond I, Pritchard GE, Ashcroft T, Avery A, Corris PA, Walters EH (1993) Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers. Thorax 48:1130–1134CrossRefPubMedGoogle Scholar
  8. 8.
    Tschernig T, Pabst R (2000) Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 68:1–8CrossRefPubMedGoogle Scholar
  9. 9.
    Ahmed S, Kussick SJ, Siddiqui AK, Bhuiya TA, Khan A, Sarewitz S, Steinberg H, Sison CP, Rai KR (2004) Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer 40:1320–1326CrossRefPubMedGoogle Scholar
  10. 10.
    Bae YA, Lee KS, Han J, Ko YH, Kim BT, Chung MJ, Kim TS (2008) Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest 133:433–440CrossRefPubMedGoogle Scholar
  11. 11.
    Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, Tomassetti S, Broccoli A, Derenzini E, Baccarani M (2007) Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. Clin Lymphoma Myeloma 7:566–572CrossRefPubMedGoogle Scholar
  12. 12.
    Xu HY, Jin T, Li RY, Ni YM, Zhou JY, Wen XH (2007) Diagnosis and treatment of pulmonary mucosa-associated lymphoid tissue lymphoma. Chin Med J (Engl) 120:648–651Google Scholar
  13. 13.
    Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH (2004) Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol 34:510–514CrossRefPubMedGoogle Scholar
  14. 14.
    Stefanovic A, Morgensztern D, Fong T, Lossos IS (2008) Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Leuk Lymphoma 49:1311–1320CrossRefPubMedGoogle Scholar
  15. 15.
    Chilosi M, Zinzani PL, Poletti V (2005) Lymphoproliferative lung disorders. Semin Respir Crit Care Med 26:490–501CrossRefPubMedGoogle Scholar
  16. 16.
    Graham BB, Mathisen DJ, Mark EJ, Takvorian RW (2005) Primary pulmonary lymphoma. Ann Thorac Surg 80:1248–1253CrossRefPubMedGoogle Scholar
  17. 17.
    Troch M, Streubel B, Petkov V, Turetschek K, Chott A, Raderer M (2007) Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 27:3633–3637PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sung Yong Oh
    • 1
    • 14
  • Won Seog Kim
    • 2
  • Jin Seok Kim
    • 2
  • Seok Jin Kim
    • 3
  • Hyuk-Chan Kwon
    • 1
    • 14
  • Dae Ho Lee
    • 4
  • Jong Ho Won
    • 5
  • In Gyu Hwang
    • 6
  • Min Kyoung Kim
    • 7
  • Soon Il Lee
    • 8
  • Yee Soo Chae
    • 9
  • Deok-Hwan Yang
    • 10
  • Gyeong-Won Lee
    • 11
  • Chul Won Choi
    • 12
  • Jinny Park
    • 13
  • Cheolwon Suh
    • 4
  • Hyo-Jin Kim
    • 1
  1. 1.Department of Internal MedicineDong-A University College of MedicineSeo-guKorea
  2. 2.Division of Hematology/Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Department of Internal MedicineYonsei University College of MedicineSeoulKorea
  4. 4.Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  5. 5.Department of Internal MedicineUniversity College of Medicine, Soon Chun Hyang UniversitySeoulKorea
  6. 6.Division of Hematology–Oncology, Department of MedicineChung-Ang UniversitySeoulKorea
  7. 7.Division of Oncology, Department of Internal MedicineYeungnam University College of MedicineDaeguKorea
  8. 8.Department of Internal MedicineDankook University College of MedicineCheonanKorea
  9. 9.Department of Hematology/OncologyKyungpook National University Hospital, Kyungpook National University School of MedicineDaeguKorea
  10. 10.Department of Hematology–OncologyChonnam National University Hwasun HospitalJeollanam-doKorea
  11. 11.Division of Hematology–Oncology, Department of Internal MedicineCollege of Medicine, Gyeongsang National UniversityJinjuKorea
  12. 12.Division of Oncology -Hematology, Department of Internal MedicineKorea University Anam Hospital, Korea University College of MedicineSeoulKorea
  13. 13.Department of Internal MedicineGachon Medical SchoolInchonKorea
  14. 14.Medical Research Center for Cancer Molecular TherapyDong-A University College of MedicineBusanKorea

Personalised recommendations